


FIG. 1A


Human PD-L1



Antibody	EC ₅₀	R-squared
1P9	35.86 ng/mL	0.9452
1P4	39.93 ng/mL	0.7664
Avelumab	36.72 ng/mL	0.9496

FIG. 1B


Cyno PD-L1



Antibody	EC ₅₀	R-squared
1P9	33.83 ng/mL	0.9596
1P4	30.58 ng/mL	0.8545
Avelumab	50.49 ng/mL	0.9539

FIG. 1C


Human PD-L1



Antibody	Absolute IC ₅₀
2M1	428.3 ng/mL
2M2	83.75 ng/mL
3M3	787.6 ng/mL
3M5	788.0 ng/mL
Avelumab	201.7 ng/mL


FIG. 1D

Cyno PD-L1




Antibody	Absolute IC ₅₀
2M1	558.6 ng/mL
2M2	166.5 ng/mL
3M3	672.5 ng/mL
3M5	234.15 ng/mL
Avelumab	162.3 ng/mL

FIG. 1E



Antibody	Absolute IC ₅₀
3B1	49.82 ng/mL
3B2	225.0 ng/mL
3B3	Undetermined
3B4	152.0 ng/mL
3B5	Undetermined
3B6	330.0 ng/mL
Avelumab	201.7 ng/mL


FIG. 1F



Antibody	Absolute IC ₅₀
3B1	56.85 ng/mL
3B2	341.0 ng/mL
3B3	Undetermined
3B4	105.7 ng/mL
3B5	325.0 ng/mL
3B6	245.8 ng/mL
Avelumab	162.3 ng/mL

FIG. 1H


1P9



Ligand	EC ₅₀	R-squared
PD-L1	95.32 ng/mL	0.9875
PD-L2	~1.107e+018 ng/mL	0.5744
B7-1/CD80	5312 ng/mL	0.8472
B7-2/CD86	1138 ng/mL	0.9136
B7-H2	~1.639e+016 ng/mL	0.9254
B7-H3	~1.653e+018 ng/mL	0.9431

FIG. 1G

1P4



Ligand	EC ₅₀	R-squared
PD-L1	478.5 ng/mL	0.9974
PD-L2	5756 ng/mL	0.8127
B7-1/CD80	~1.058e+018 ng/mL	0.8748
B7-2/CD86	~1.173e+018 ng/mL	0.8180
B7-H2	~1.817e+018 ng/mL	0.7405
B7-H3	~7.057e+017 ng/mL	0.9211

FIG. 2A

PD-L1-expressing CHO






FIG. 2B

wtCHO



Antibody	EC ₅₀	R-squared
1P4 wtFc	45.69 ng/mL	0.9985
1P4 EKO	45.54 ng/mL	0.9991
1P9 wtFc	19.89 ng/mL	0.9973
1P9 EKO	18.65 ng/mL	0.9982

FIG. 3



Antibody	EC ₅₀	R-squared
1P4	41.55 ng/mL	0.9996
1P9	15.86 ng/mL	0.9920
Avelumab	54.08 ng/mL	0.9990

FIG. 4A




FIG. 4B




FIG. 5A

Human PD-L1




FIG. 5B

Cyno PD-L1




FIG. 6A

PD-L1-expressing CHO






FIG. 6B

wtCHO





Conjugate	EC ₅₀	R-squared
1P4-IR700 wt	133.4 ng/mL	0.9995
1P4-IR700 EKO	145.0 ng/mL	0.9990
1P9-IR700 wt	15.63 ng/mL	0.9964
1P9-IR700 EKO	17.42 ng/mL	0.9978

FIG. 7A



Conjugate	EC ₅₀	R-squared
1P4-IR700	133.4 ng/mL	0.9987
1P9-IR700	12.89 ng/mL	0.9917
Avelumab-IR700	300.1 ng/mL	0.9987









FIG. 7E






FIG. 8B




FIG. 8C





FIG. 8D



Conjugate	Donor 1		Donor 2		Donor 3	
	EC ₅₀ (ng/mL)	R ²	EC ₅₀ (ng/mL)	R ²	EC ₅₀ (ng/mL)	R ²
■ 1P9-IR700	21.17	0.9866	24.72	0.9922	14.44	0.9944
△ Avelumab-IR700	50.34	0.9794	60.07	0.9925	50.98	0.9866




FIG. 8E

FIG. 9A

Avelumab-IR700




FIG. 9B

1P9-IR700





FIG. 9C






FIG. 10B

